Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Carlo Incerti Sells 16,500 Shares

by · The Markets Daily

Dyne Therapeutics, Inc. (NASDAQ:DYNGet Free Report) Director Carlo Incerti sold 16,500 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $28.73, for a total value of $474,045.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Dyne Therapeutics Stock Up 3.3 %

Shares of Dyne Therapeutics stock opened at $29.34 on Tuesday. The firm has a market cap of $2.99 billion, a price-to-earnings ratio of -8.24 and a beta of 1.10. Dyne Therapeutics, Inc. has a 52-week low of $10.03 and a 52-week high of $47.45. The company’s 50-day simple moving average is $32.42 and its 200-day simple moving average is $35.26.

Dyne Therapeutics (NASDAQ:DYNGet Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.39 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Stifel Nicolaus upped their target price on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a report on Friday, August 16th. Oppenheimer reissued an “outperform” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. StockNews.com lowered Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. Morgan Stanley increased their price objective on Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Finally, JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $43.00 to $35.00 in a research report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $51.40.

Get Our Latest Report on DYN

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC increased its holdings in Dyne Therapeutics by 69.7% in the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after buying an additional 3,707,734 shares in the last quarter. RTW Investments LP increased its stake in Dyne Therapeutics by 6.8% in the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock valued at $244,926,000 after purchasing an additional 431,503 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Dyne Therapeutics by 47.3% during the third quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock worth $244,755,000 after purchasing an additional 2,189,339 shares during the last quarter. RA Capital Management L.P. boosted its position in Dyne Therapeutics by 5.5% during the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock worth $229,211,000 after purchasing an additional 331,940 shares in the last quarter. Finally, State Street Corp grew its holdings in Dyne Therapeutics by 13.8% in the third quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after purchasing an additional 440,890 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Further Reading